Syncromune
Manufacturing · Florida, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
2919 E Commercial Blvd, Fort Lauderdale,...Website
www.syncromune.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
2
2
1
1
1
1
About Syncromune
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival. The company is currently developing SYNC-T, a novel and personalized in situ therapy that combines partial tumor oncolysis and a multi-target biologic drug. The SYNC-T combination approach is designed to target multiple mechanisms of cancer, promoting in situ immune activation while battling immunosuppression. The goal is to activate T cells, enabling the immune system to recognize and attack cancer throughout the body and defend with immune memory. The first two candidates, SV-101 and SV-102, are currently in Phase 1 trials.Explore more
Syncromune Org Chart
Get the full picture
Sign in to uncover key details.
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Syncromune your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Syncromune is spiking on competitors!
Earning: See what the market has to say on Syncromune recently announced quarterly report
Syncromune, which may be a good buyer, showed buying intent in Masked Content Topic
Product Launch: Get notified when Syncromune launches new products
Click to see if Syncromune had a recent Job posting/layoffs
Funding: Get notified immidiatlly once Syncromune has new funding data
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Congratulate Masked Content for being promoted to Masked Content at Syncromune
Check if Syncromune has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Recommended Actions
Find VP level buyers at Syncromune
Find 3 more new buyers
Compare Similar Companies to Syncromune
Compare insights from companies similar to Syncromune, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Syncromune is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Syncromune is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Syncromune.
Syncromune financials insights
Gather financial insights about Syncromune, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2024
Series A
$100M
Syncromune Tech Stack
A closer look at the technologies used by Syncromune
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Project
Laboratory Operations, Medical Research, Clinical Operations
New Hire
Executive Move
Executive Moves, New Hire
New Hire
Executive Move
Executive Moves, New Hire
Event
Product Marketing, Events, Learning & Development, Software, Bioengineering, Pharmaceuticals, Public Health, Field /Outside Sales, Field Marketing, Healthcare Technology, Patient Experience
Syncromune News & Media
Syncromune Continues to Strengthen Executive and Clinical Leadership with Appointment of Dr. Stephen P. Dale, M.D., as Chief Medical Officer
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Jan. 06, 2026 (GLOBE NEWSWIRE) -- Syncromune® Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T™, an in situ platform combination immunotherapy optimized for solid tumor cancers, today announced the appointment of Stephen P. Dale, M.D., as Chief Medical Officer.Syncromune®, Inc. Presents Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at Society of Urological Oncology 26th Annual Meeting
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Dec. 04, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company dedicated to the development of SYNC-T, an in situ platform combination therapy optimized for solid tumor cancers, today announced the presentation of findings from its Phase 1 clinical study of SYNC-T Therapy SV-102 in patients with metastatic castration-resistant prostate cancer (mCRPC) and metastatic hormone-sensitive prostate cancer (mHSPC). The datSyncromune®, Inc. to Present Phase 1 Data Highlighting Resolution of Bone Metastases in Metastatic Prostate Cancer Patients at the Society of Urological Oncology 26th Annual Meeting
FORT LAUDERDALE, Fla. and WEST DES MOINES, Iowa, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Syncromune®, Inc., a clinical-stage biopharmaceutical company pioneering SYNC-T, an in situ personalized combination immunotherapy platform for solid tumor cancers, today announced that an abstract has been accepted for presentation at the Society of Urologic Oncology (SUO) 26th Annual Meeting being held December 2-5, 2025 in Phoenix, Arizona.Syncromune® Appoints Industry Veteran Kerri-Ann Millar as Chief Financial Officer to Advance Corporate Growth Initiatives and Clinical Development Program
Millar to Lead Financial Strategy as Syncromune Scales Development of the SYNC-T® Novel Immunotherapy Platform for Solid Tumor Cancers Millar to Lead Financial Strategy as Syncromune Scales Development of the SYNC-T® Novel Immunotherapy Platform for Solid Tumor Cancers
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Frequently Asked Questions Regarding Syncromune
Sign Up For FreeTo access detailed company insights
Syncromune is a privately held, clinical-stage biopharmaceutical company dedicated to the development of an in situ platform therapy optimized for metastatic solid tumor cancers that aims to achieve high response rates with potentially improved survival. The company is currently developing SYNC-T, a novel and personalized in situ therapy that combi... Read More
